tradingkey.logo
tradingkey.logo
検索

Avalyn Pharma Ord Shs (Proposed)

AVLN
ウォッチリストに追加
30.280USD
-0.310-1.01%
終値 11-13 16:00(ET)
1.34B時価総額
0.00直近12ヶ月PER

Avalyn Pharma Ord Shs (Proposed)について 企業名

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Avalyn Pharma Ord Shs (Proposed) プロフィール

企業コード- -
会社名- -
上場日- -
最高経営責任者「CEO」- -
従業員数- -
証券種類- -
決算期末- -
本社所在地- -
都市- -
証券取引所- -
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コード- -
上場日- -
最高経営責任者「CEO」- -

Avalyn Pharma Ord Shs (Proposed)の経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill Carroll
Ms. Jill Carroll
Independent Director
Independent Director
--
--
Mr. Jon Congleton
Mr. Jon Congleton
Independent Director
Independent Director
--
--
Dr. David Friedman, M.D.
Dr. David Friedman, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--

よくある質問

Avalyn Pharma Ord Shs (Proposed)の上位5名の株主は誰ですか?

Avalyn Pharma Ord Shs (Proposed)の上位5名の株主は以下のとおりです。Dr. Ketan Patel, M.D.
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。